(Q38826378)

English

Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.

scientific article published on 21 April 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28431196%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28431196%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Benoit Peyronnet

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28431196%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28431196%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Gilles Karsenty

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28431196%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

author name string

Florie Bottet

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28431196%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Romain Boissier

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28431196%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Bénédicte Reiss

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28431196%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Jean G Previnaire

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28431196%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Andrea Manunta

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28431196%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Jacques Kerdraon

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28431196%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Alain Ruffion

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28431196%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Loïc Lenormand

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28431196%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Brigitte Perrouin Verbe

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28431196%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Sarah Gaillet

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28431196%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Groupe d'Etude de Neuro-Urologie de Langue Française (GENULF) and the committee of NeuroUrology of the French Association of Urology (AFU)

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28431196%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

publication date

21 April 2017

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28431196%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Neurourology and Urodynamics

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28431196%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

37

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28431196%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28431196%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

291-297

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28431196%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FNAU.23291

21 January 2018

Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity

1 reference

https://api.crossref.org/works/10.1002%2FNAU.23291

21 January 2018

Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.

1 reference

https://api.crossref.org/works/10.1002%2FNAU.23291

21 January 2018

Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).

1 reference

https://api.crossref.org/works/10.1002%2FNAU.23291

21 January 2018

Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA).

1 reference

https://api.crossref.org/works/10.1002%2FNAU.23291

21 January 2018

Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study

1 reference

https://api.crossref.org/works/10.1002%2FNAU.23291

21 January 2018

Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity.

1 reference

https://api.crossref.org/works/10.1002%2FNAU.23291

21 January 2018

The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it.

1 reference

https://api.crossref.org/works/10.1002%2FNAU.23291

21 January 2018

Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications

1 reference

https://api.crossref.org/works/10.1002%2FNAU.23291

21 January 2018

Using translational medicine to understand clinical differences between botulinum toxin formulations

1 reference

https://api.crossref.org/works/10.1002%2FNAU.23291

21 January 2018

Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products

1 reference

https://api.crossref.org/works/10.1002%2FNAU.23291

21 January 2018

Pharmacokinetic properties of different formulations of botulinum neurotoxin type A.

1 reference

https://api.crossref.org/works/10.1002%2FNAU.23291

21 January 2018

Clinical comparability of marketed formulations of botulinum toxin

1 reference

https://api.crossref.org/works/10.1002%2FNAU.23291

21 January 2018

Pharmacology of botulinum toxin: differences between type A preparations

1 reference

https://api.crossref.org/works/10.1002%2FNAU.23291

21 January 2018

A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia

1 reference

https://api.crossref.org/works/10.1002%2FNAU.23291

21 January 2018

Minimal effective dose of dysport and botox in a rat model of neurogenic detrusor overactivity.

1 reference

https://api.crossref.org/works/10.1002%2FNAU.23291

21 January 2018

Expression of cleaved SNAP-25 after bladder wall injection of onabotulinumtoxina or abobotulinumtoxina: A comparative study in the mice

1 reference

https://api.crossref.org/works/10.1002%2FNAU.23291

21 January 2018

DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1

1 reference

https://api.crossref.org/works/10.1002%2FNAU.23291

21 January 2018

Identifiers

10.1002/NAU.23291

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28431196%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28431196%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38826378&oldid=2078056555"